Chung JR, et al. - Given that current multivalent influenza vaccine products afford protection against influenza A(H1N1)pdm09, A(H3N2), and B lineage viruses, researchers here sought to determine the number of vaccine-prevented influenza-associated illnesses, medical visits, hospitalizations, and deaths for 2018–2019 influenza season in the US that included prolonged circulation of both A(H1N1)pdm09 viruses well-matched to the vaccine strain, and A(H3N2) viruses the majority of which were mismatched to the vaccine. Using a mathematical model and Monte Carlo algorithm, they determined numbers and 95% uncertainty intervals (UI) of influenza-associated outcomes averted by vaccination in the US. As per estimates, substantial influenza-associated disease was prevented by influenza vaccination including hospitalizations and deaths in the US; this was observed primarily due to its effectiveness against A(H1N1)pdm09. the vaccination averted 4.4 million (95% UI: 3.4 million–7.1 million) illnesses, 2.3 million (95% UI: 1.8 million–3.8 million) medical visits, 58,000 (95% UI: 30,000–156,000) hospitalizations, and 3,500 (95% UI: 1,000–13,000) deaths. The findings emphasize the significance of influenza vaccination, highlighting that vaccines markedly reduce illness and associated healthcare utilization even in a season in which a vaccine component does not match to a circulating virus.